2-chloro-5-fluoro-N-(1-hydroxymethyl-cyclopentyl)-nicotinamide | 837377-34-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-5-fluoro-N-(1-hydroxymethyl-cyclopentyl)-nicotinamide
• 英文别名: 2-chloro-5-fluoro-N-[1-(hydroxymethyl)cyclopentyl]pyridine-3-carboxamide
• CAS: 837377-34-1
• 化学式: C₁₂H₁₄ClFN₂O₂
• 分子量: 272.707
• InChiKey: PCJIZNVPFKTECA-UHFFFAOYSA-N

物化性质

• 沸点：
  407.4±45.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-chloro-5-fluoro-N-(1-hydroxymethyl-cyclopentyl)-nicotinamide 、 4-(甲硫基)苯酚 在 caesium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 16.0h， 生成 5-fluoro-N-(1-hydroxymethyl-cyclopentyl)-2-(4-methylsulfanyl-phenoxy)-nicotinamide
  参考文献：
  名称：

  [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS
  [FR] DERIVES DE NICOTINAMIDE AGISSANT COMME INHIBITEURS DE PDE4

  摘要：

  这项发明涉及式(I)的烟酰胺衍生物，以及含有该类衍生物的药物组合物，以及将这些衍生物用作PDE4抑制剂的用途，其中R7连接到苯环的3-或4-位，并且为S(O)pR8，R8为(C1-C4)烷基，可选择地被(C3-C6)环烷基取代；m为0或1；L为(C3-C8)非芳香环；其余变量如索权中所定义。

  公开号：

  WO2005009966A1
• 作为产物：
  描述：

  1-氨基-1-环戊基甲醇 、 2-氯-5-氟烟酸 在 4-二甲氨基吡啶 、 N,N'-羰基二咪唑 作用下， 以 二氯甲烷 为溶剂， 反应 18.25h， 生成 2-chloro-5-fluoro-N-(1-hydroxymethyl-cyclopentyl)-nicotinamide
  参考文献：
  名称：

  [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS
  [FR] DERIVES DE NICOTINAMIDE AGISSANT COMME INHIBITEURS DE PDE4

  摘要：

  这项发明涉及式(I)的烟酰胺衍生物，以及含有该类衍生物的药物组合物，以及将这些衍生物用作PDE4抑制剂的用途，其中R7连接到苯环的3-或4-位，并且为S(O)pR8，R8为(C1-C4)烷基，可选择地被(C3-C6)环烷基取代；m为0或1；L为(C3-C8)非芳香环；其余变量如索权中所定义。

  公开号：

  WO2005009966A1

文献信息

• Nicotinamide derivatives useful as PDE4 inhibitors
  申请人：Bailey Simon

  公开号：US20050032838A1

  公开（公告）日：2005-02-10

  This invention relates to nicotinamide derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing, and the uses of such derivatives: wherein R 1 is selected from the group consisting of hydrogen, methyl or halo; R 7 is attached to the 3- or 4-position of the phenyl ring and is S(O) p R 8 , R 8 is (C 1 -C 4 )alkyl optionally substituted by (C 3 -C 6 )cycloalkyl; p is 0, 1 or 2; R 6 is selected from the group consisting of hydrogen, halo, (C 1 -C 3 )alkyl and (C 1 -C 3 )alkoxy; m is 0 or 1; L is a (C 3 -C 8 )carbocyclic non-aromatic ring; R 2 is hydrogen, hydroxy, (C 1 -C 3 )alkoxy, (C 1 -C 3 )alkyl (optionally substituted by hydroxy or by (C 1 -C 3 )alkoxy), CO 2 R 9 , NR 10 R 11 or CONR 10 R 11 ; R 3 is hydrogen or (C 1 -C 3 )alkyl; R 9 is hydrogen or (C 1 -C 3 )alkyl; R 10 and R 11 are each independently hydrogen, or, are selected from the group consisting of: (C 1 -C 6 )alkyl optionally substituted by phenyl or a 5- or 6-membered heterocyclic ring incorporating 1 to 3 heteroatom(s) independently selected from N, O and S, which phenyl is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and which heterocyclic ring is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or oxo; (C 3 -C 8 )cycloalkyl; CO((C 1 -C 6 )alkyl) optionally substituted by hydroxy, halo, (C 3 -C 8 )cycloalkyl, (C 1 -C 3 )alkoxy, phenyl or a 5- or 6-membered heterocyclic ring incorporating 1 to 3 heteroatom(s) independently selected from N, O and S, which phenyl is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and which heterocyclic ring is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or oxo; CO(R 12 ), wherein R 12 is (C 3 -C 8 )cycloalkyl optionally substituted by (C 1 -C 3 )alkyl or R 12 is phenyl or a 5- or 6-membered heterocyclic ring incorporating 1 to 3 heteroatom(s) independently selected from N, O and S, which phenyl is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and which heterocyclic ring is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or oxo; and CO 2 (C 1 -C 3 )alkyl); or R 10 and R 11 are taken together with the N atom to which they are attached to form a 5- or 6-membered lactam.

  本发明涉及化合物(I)的烟酰胺衍生物，以及制备这些衍生物的中间体的制备方法，含有这些衍生物的制药组合物，以及这些衍生物的用途：其中R1选自氢、甲基或卤素的群；R7附加到苯环的3-或4-位上，为S（O）pR8，R8为（C1-C4）烷基，可选地被（C3-C6）环烷基取代，p为0、1或2；R6选自氢、卤素、（C1-C3）烷基和（C1-C3）烷氧基的群；m为0或1；L为（C3-C8）非芳香环烷基；R2为氢、羟基、（C1-C3）烷氧基、（C1-C3）烷基（可选地被羟基或（C1-C3）烷氧基取代）、CO2R9、NR10R11或CONR10R11的群；R3为氢或（C1-C3）烷基；R9为氢或（C1-C3）烷基；R10和R11各自独立地选自以下群：（C1-C6）烷基，可选地被苯基或包含1至3个杂原子（独立选自N、O和S）的5-或6-成员杂环取代，其中苯基可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基或（C1-C3）烷氧基，而杂环可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基、（C1-C3）烷氧基或氧代基；（C3-C8）环烷基；CO（（C1-C6）烷基），可选地被羟基、卤素、（C3-C8）环烷基、（C1-C3）烷氧基、苯基或包含1至3个杂原子（独立选自N、O和S）的5-或6-成员杂环取代，其中苯基可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基或（C1-C3）烷氧基，而杂环可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基、（C1-C3）烷氧基或氧代基；CO（R12），其中R12为（C3-C8）环烷基，可选地被（C1-C3）烷基取代，或R12为苯基或包含1至3个杂原子（独立选自N、O和S）的5-或6-成员杂环，其中苯基可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基或（C1-C3）烷氧基，而杂环可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基、（C1-C3）烷氧基或氧代基；以及R10和R11一起与它们所附着的N原子形成5-或6-成员内酰胺。
• NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS
  申请人：Pfizer Limited

  公开号：EP1651609A1

  公开（公告）日：2006-05-03
• US7141586B2
  申请人：——

  公开号：US7141586B2

  公开（公告）日：2006-11-28
• [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS<br/>[FR] DERIVES DE NICOTINAMIDE AGISSANT COMME INHIBITEURS DE PDE4
  申请人：PFIZER LTD

  公开号：WO2005009966A1

  公开（公告）日：2005-02-03

  This invention relates to nicotinamide derivatives of formula (I) and to pharmaceutical compositions containing, and the uses of such derivatives as PDE4 inhibitors wherein R7 is attached to the 3- or 4-position of the phenyl ring and is S(O)pR8, R8 is (C1-C4)alkyl optionally substituted by (C3-C6)cycloalkyl; m is 0 or 1; L is a (C3-C8)carbocyclic non-aromatic ring; and the remaining variables are as defined in the claims.

  这项发明涉及式(I)的烟酰胺衍生物，以及含有该类衍生物的药物组合物，以及将这些衍生物用作PDE4抑制剂的用途，其中R7连接到苯环的3-或4-位，并且为S(O)pR8，R8为(C1-C4)烷基，可选择地被(C3-C6)环烷基取代；m为0或1；L为(C3-C8)非芳香环；其余变量如索权中所定义。